4//SEC Filing
Stark David Matthew 4
Accession 0001209191-23-017161
CIK 0000818686other
Filed
Mar 7, 7:00 PM ET
Accepted
Mar 8, 4:05 PM ET
Size
7.5 KB
Accession
0001209191-23-017161
Insider Transaction Report
Form 4
Stark David Matthew
Exec. VP Chief Legal Officer
Transactions
- Sale
Ordinary Shares
2023-03-06$9.93/sh−16,491$163,770→ 52,449.39 total - Sale
Ordinary Shares
2023-03-07$9.43/sh−49,475$466,445→ 2,974.39 total
Footnotes (4)
- [F1]The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
- [F2]The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.86 to $10.045, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.
- [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.37 to $9.725, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.
Documents
Issuer
TEVA PHARMACEUTICAL INDUSTRIES LTD
CIK 0000818686
Entity typeother
Related Parties
1- filerCIK 0001722360
Filing Metadata
- Form type
- 4
- Filed
- Mar 7, 7:00 PM ET
- Accepted
- Mar 8, 4:05 PM ET
- Size
- 7.5 KB